JP2024514255A - 増強された抗ｈｖｅｍ抗体及びその使用 - Google Patents

増強された抗ｈｖｅｍ抗体及びその使用 Download PDF

Info

Publication number
JP2024514255A
JP2024514255A JP2023561005A JP2023561005A JP2024514255A JP 2024514255 A JP2024514255 A JP 2024514255A JP 2023561005 A JP2023561005 A JP 2023561005A JP 2023561005 A JP2023561005 A JP 2023561005A JP 2024514255 A JP2024514255 A JP 2024514255A
Authority
JP
Japan
Prior art keywords
seq
antibody
amino acid
cdr
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023561005A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024514255A5 (https=
Inventor
グリーンバーグ，エヤル
ガロア－ハスケル，ジリ
メルハヴィ－ショハム，エフラット
マーケル，ガル
Original Assignee
４シー バイオメッド リミテッド
シバ インパクト リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ４シー バイオメッド リミテッド, シバ インパクト リミテッド filed Critical ４シー バイオメッド リミテッド
Publication of JP2024514255A publication Critical patent/JP2024514255A/ja
Publication of JP2024514255A5 publication Critical patent/JP2024514255A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2023561005A 2021-04-01 2022-03-31 増強された抗ｈｖｅｍ抗体及びその使用 Pending JP2024514255A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163169335P 2021-04-01 2021-04-01
US63/169,335 2021-04-01
PCT/IL2022/050348 WO2022208505A1 (en) 2021-04-01 2022-03-31 Enhanced anti-hvem antibodies and use thereof

Publications (2)

Publication Number Publication Date
JP2024514255A true JP2024514255A (ja) 2024-03-29
JP2024514255A5 JP2024514255A5 (https=) 2025-04-07

Family

ID=83458354

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023561005A Pending JP2024514255A (ja) 2021-04-01 2022-03-31 増強された抗ｈｖｅｍ抗体及びその使用

Country Status (9)

Country Link
US (1) US20240067742A1 (https=)
EP (1) EP4320162A4 (https=)
JP (1) JP2024514255A (https=)
KR (1) KR20240047954A (https=)
CN (1) CN117412990A (https=)
AU (1) AU2022251320A1 (https=)
CA (1) CA3213956A1 (https=)
IL (1) IL307407A (https=)
WO (1) WO2022208505A1 (https=)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015517470A (ja) * 2012-05-04 2015-06-22 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 親和性成熟抗ｃｃｒ４ヒト化モノクローナル抗体および使用法
JP2017534247A (ja) * 2015-06-09 2017-11-24 北京東方百泰生物科技有限公司Ｂｅｉｊｉｎｇ Ｄｏｎｇｆａｎｇ Ｂｉｏｔｅｃｈ Ｃｏ．， Ｌｔｄ． 抗ｐｄ−１のモノクローナル抗体およびその獲得方法
WO2020072705A1 (en) * 2018-10-03 2020-04-09 Nepenthe Biosciences, Llc Anti-cd79 antibodies and their uses
WO2020222235A1 (en) * 2019-04-29 2020-11-05 4C Biomed Inc. Anti-hvem antibodies and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014183885A1 (en) * 2013-05-17 2014-11-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of the btla/hvem interaction for use in therapy
MX2019007963A (es) * 2017-01-06 2019-10-21 Iovance Biotherapeutics Inc Expansion de linfocitos infiltrantes de tumor (til) con agonistas de la superfamilia de recptor de factor de necrosis tumoral (tnfrsf) y combinaciones terapeuticas de til- y agonistas de tnfrsf.
WO2022074648A1 (en) * 2020-10-05 2022-04-14 4C Biomed Limited Marker for response to pd-1/pd-l1 immunotherapy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015517470A (ja) * 2012-05-04 2015-06-22 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 親和性成熟抗ｃｃｒ４ヒト化モノクローナル抗体および使用法
JP2017534247A (ja) * 2015-06-09 2017-11-24 北京東方百泰生物科技有限公司Ｂｅｉｊｉｎｇ Ｄｏｎｇｆａｎｇ Ｂｉｏｔｅｃｈ Ｃｏ．， Ｌｔｄ． 抗ｐｄ−１のモノクローナル抗体およびその獲得方法
WO2020072705A1 (en) * 2018-10-03 2020-04-09 Nepenthe Biosciences, Llc Anti-cd79 antibodies and their uses
WO2020222235A1 (en) * 2019-04-29 2020-11-05 4C Biomed Inc. Anti-hvem antibodies and use thereof

Also Published As

Publication number Publication date
EP4320162A4 (en) 2025-07-23
CA3213956A1 (en) 2022-10-06
WO2022208505A1 (en) 2022-10-06
WO2022208505A9 (en) 2023-11-23
AU2022251320A1 (en) 2023-10-19
KR20240047954A (ko) 2024-04-12
AU2022251320A9 (en) 2023-10-26
CN117412990A (zh) 2024-01-16
IL307407A (en) 2023-12-01
US20240067742A1 (en) 2024-02-29
EP4320162A1 (en) 2024-02-14

Similar Documents

Publication Publication Date Title
CN111699199B (zh) Ox40抗体及其用途
CN111454361B (zh) 与cd40结合的抗体及其用途
JP2022130393A (ja) 抗ｃｔｌａ４－抗ｐｄ－１二機能性抗体、その医薬組成物および使用
EP3970749A1 (en) Anti-tim-3 antibodies and use thereof
KR20210143192A (ko) 변형된 Fc 단편, 이를 포함하는 항체 및 이의 응용
KR20160006168A (ko) 인간화 항-cd134(ox40) 항체 및 이의 용도
CN111808192B (zh) 结合lag3的抗体及其用途
CN114981301B (zh) Pd1和vegfr2双结合剂
KR20220070201A (ko) 항-pd-1 항체 및 이의 용도
CN112625130A (zh) 抗-tigit抗体及使用之方法
CN115466327B (zh) 结合tigit的抗体及其用途
CN114106182A (zh) 抗tigit的抗体及其用途
JP7625516B2 (ja) Ｈｅｒ２ ｓ３１０ｆ特異的な抗原結合分子
CN115073599A (zh) 结合pd-l1的抗体及其用途
US20240067742A1 (en) Enhanced anti-hvem antibodies and use thereof
CN118900847A (zh) 结合b7-h3的抗体及其用途
CN117255804A (zh) 针对人4-1bb的抗体及其变体
HK40009892A (en) Antibodies binding ox40 and uses thereof
HK40009892B (en) Antibodies binding ox40 and uses thereof
HK40027802A (en) Antibodies binding cd40 and uses thereof
HK40026863A (en) Antibodies binding cd40 and uses thereof
HK40027804A (en) Antibodies binding cd40 and uses thereof
HK40026862A (en) Antibodies binding cd40 and uses thereof
HK40027803A (zh) 结合cd40的抗体及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250328

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250328

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260127

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260428